Led by Dr. Jeffrey Cummings , the Observatory will enable broader access to the biomarker pipeline, accelerating the development of novel drugs that will be used in combination with available drugs on the market. NEW YORK , Sept.
18, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced a new investment to develop a first-of-its-kind Biomarker Observatory that will provide a comprehensive overview of the Alzheimer's biomarkers pipeline, including blood tests, brain scans, digital devices, and other tools that can help diagnose and monitor the disease. These efforts will be led by renowned clinical trialist Jeffrey Cummings , MD, ScD, Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at University of Nevada, Las Vegas with Co-Principal Investigator Feixiong Cheng , PhD, from the Laboratory of Network Medicine at Cleveland Clinic. This Observatory will fill a critical gap by creating the first thorough overview of the biomarker pipeline, serving as a key resource to catalyze progress in drug development.
"Biomarkers are integral for accelerating drug development and enabling an early and accurate diagnosis," says Howard Fillit , MD, Co-Founder and Chief Science Officer of the ADDF. "Innovative initiatives like the Biomarker Observatory will expedite the development of new biomarkers, which are needed to support the incredibly robust and diverse drug pipeline where nearly 75% of drugs in development are exp.